There are 3164 resources available
Welcome and Introductions
Presenter: Neal Shore
Session: Pfizer Oncology - Breaking new ground: PARPi + ARPi combination therapy in mCRPC
Resources:
Webcast
Introduction
Presenter: Eric Van Cutsem
Session: Servier - Advancements in Metastatic Pancreatic Cancer: Which perspectives for patients?
Resources:
Webcast
Unveiling real-world evidence: Exploring the PSA Response in mHSPC
Presenter: Alison Birtle
Session: Johnson & Johnson - Optimising the personalisation of GU cancer care
Resources:
Webcast
Beyond BRCA: examining the evidence for novel PARPi combinations in mCRPC
Presenter: Axel Merseburger
Session: Pfizer Oncology - Breaking new ground: PARPi + ARPi combination therapy in mCRPC
Resources:
Webcast
Navigating the latest news and guidelines in Metastatic Pancreatic Cancer
Presenter: Gerald Prager
Session: Servier - Advancements in Metastatic Pancreatic Cancer: Which perspectives for patients?
Resources:
Webcast
Efficacy and QoL in mHSPC – finding the right balance
Presenter: Alejo Rodriguez-Vida
Session: Johnson & Johnson - Optimising the personalisation of GU cancer care
Resources:
Webcast
Harnessing the potential of HRR gene profiling to inform treatment decisions
Presenter: Eleni Efstathiou
Session: Pfizer Oncology - Breaking new ground: PARPi + ARPi combination therapy in mCRPC
Resources:
Webcast
Integrating new data into current clinical practice: Key learnings from Napoli 3 study
Presenter: Teresa Macarulla Mercade
Session: Servier - Advancements in Metastatic Pancreatic Cancer: Which perspectives for patients?
Resources:
Webcast
The significance of BRCA1/2 mutations in mCRPC outcomes
Presenter: Elena Verzoni
Session: Johnson & Johnson - Optimising the personalisation of GU cancer care
Resources:
Webcast
Patient-centered approaches - who should we treat with PARPi and how?
Presenter: Neal Shore, Axel Merseburger, Eleni Efstathiou
Session: Pfizer Oncology - Breaking new ground: PARPi + ARPi combination therapy in mCRPC
Resources:
Webcast